Amarenco Raises 300 Million Euros to Support Its Growth as a Solar IPP and Storage Energy Player
Amarenco, a Franco-Irish company specialising in photovoltaic energy, has just completed a new round of capital raising for 300 m€. This latest round allows Arjun Infrastructure Partners, to acquire a minority stake in Amarenco. Arjun Infrastructure joins, alongside a pool of investors from the Crédit Agricole Group1, Tikehau Capital2, an alternative asset management group, which has made a significant contribution to Amarenco's growth since 2020.
Why this third round of financing 3 years after the first?
With uninterrupted growth every year since its creation, Amarenco Group has the capacity, thanks to this third round of capital raising, to take another important step towards achieving its objectives; In particular, in terms of ecosystem regeneration, by initiating, for example, the first micro-forest and soil regeneration projects (to produce regenerative energy) in 2023, or by successfully implementing energy storage systems such as the flagship 100 megawatt-hour "Claudia" project.3
More generally, this new round of financing will make it possible to fund the company's development ambitions over the coming months/years:
- Converting its multi-GW projects into assets across all of its geographies over the next 3 years
- Continue to expand across all of its 3 strategic pillars, i.e. solar, energy storage and agripv infrastructures, with a particular focus on corporate offtakers by supporting them in achieving their net carbon ambitions and long term power price hedging strategies across their sites all their geographies.
As part of this fundraising, Julian Skinner and Romain Py from Arjun Infrastructure join Amarenco's board of directors, which also includes Mathieu Badjeck and Pierrre Abadie, co-heads of Tikehau Capital's Private Equity Energy Transition practice.
1 IDIA Capital Investissement, Sofilaro, Grand Sud Ouest Capital and Nord Midi-Pyrénées Développement
2 Tikehau Capital has been a shareholder of Amarenco since 2020 through its European private equity strategy “T2 Energy Transition Fund” dedicated to ecarbonization.
3 The “Claudia” project is a lithium-ion battery storage project with a capacity of 105 MW / 98 MWh, located on industrial wasteland in Gironde (33)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005111/en/
- For Amarenco: Profile Agency
Olivia Chabbert - firstname.lastname@example.org - +33156267200
- For Arjun Infrastructure Partners:
Chris Wilson - email@example.com - +44(0)7840235623
- For Tikehau Capital:
Valérie Sueur – firstname.lastname@example.org and Juliette Mouraret - email@example.com
- For IDIA Capital Investissement:
Audrey Tournant – firstname.lastname@example.org – +33 (0)614401002
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release
RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict
IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release
IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating
Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release
Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla
Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release
Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m
Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™7.6.2023 17:00:00 EEST | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005502/en/ CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mous
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom